Abstract
A novel synthetic gene transfer vector was evaluated for tumor cell-specific targeted gene delivery. The folate receptor is a tumor marker overexpressed in more than 90% of ovarian carcinomas and large percentages of other human tumors. Folic acid is a high affinity ligand for the folate receptor that retains its binding affinity upon derivatization via its gamma carboxyl. Folate conjugation, therefore, presents a potential strategy for tumor-selective targeted gene delivery. In the current study, we investigated a series of folate conjugates of the cationic polymer polyethylenimine (PEI) for potential use in gene delivery. A plasmid containing a luciferase reporter gene (pCMV-Luc) and the folate receptor expressing human oral cancer KB cells were used to monitor gene transfer efficiency in vitro. Transfection activity of polyplexes containing unmodified polyethylenimine was highly dependent on the positive to negative charge (or the N/P) ratio. Folate directly attached to PEI did not significantly alter the transfection activity of its DNA complexes compared to unmodified PEI. Modification of PEI by polyethyleneglycol (PEG) led to a partial inhibition of gene delivery compared to unmodified PEI. Attaching folates to the distal termini of PEG-modified PEI greatly enhanced the transfection activity of the corresponding DNA complexes over the polyplexes containing PEG-modified PEI. The enhancements were observed at all N/P ratios tested and could be blocked partially by co-incubation with 200 μM free folic acid, which suggested the involvement of folate receptor in gene transfer. Targeted vectors based on the folate-PEG-PEI conjugate are potentially useful as simple tumor-specific vehicles of therapeutic genes.
References
- 1.Garin-Chesa P, Campbell I, Saigo PE, Lewis JLJ, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993;42:557–567. [PMC free article] [PubMed] [Google Scholar]
- 2.Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer. 1994;73:2432–2443. doi: 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
- 3.Crippa F, Buraggi G, DiRe M, Gasparini M, Seregni E, Canervari S, Gadina M, Presti A, Marini A, Seccamani E. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer. 1991;27:724–724. doi: 10.1016/0277-5379(91)90174-c. [DOI] [PubMed] [Google Scholar]
- 4.Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, Buraggi G, Bombardieri E. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer. 1995;31A:686–690. doi: 10.1016/0959-8049(94)00454-D. [DOI] [PubMed] [Google Scholar]
- 5.Casalini P, Luison E, Menard S, Colnaghi MI, Paganelli G, Canervari S. Tumor pretargeting role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med. 1997;38:1378–1381. [PubMed] [Google Scholar]
- 6.Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, Siccardi A, Fazio F. Two-step tumor targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med. 1992;19:322–322. doi: 10.1007/BF00177053. [DOI] [PubMed] [Google Scholar]
- 7.Molthoff C, Buist M, Kenemans P, Pinedo H, Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18 reactive with an ovarian cancer-associated antigen. J Nucl Med. 1992;33:2000–2000. [PubMed] [Google Scholar]
- 8.Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A. 1991;88:5572–5576. doi: 10.1073/pnas.88.13.5572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269:3198–3204. [PubMed] [Google Scholar]
- 10.Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1994;1233:134–144. doi: 10.1016/0005-2736(94)00235-h. [DOI] [PubMed] [Google Scholar]
- 11.Lee RJ, Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem. 1996;271:8481–8487. doi: 10.1074/jbc.271.14.8481. [DOI] [PubMed] [Google Scholar]
- 12.Lee R, Wang S, Low P. Measurement of endosomal pH following folate receptor-mediated endocytosis. Biochim Biophys Acta. 1996;1312:237–242. doi: 10.1016/0167-4889(96)00041-9. [DOI] [PubMed] [Google Scholar]
- 13.Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. Delivery of antisense oligodeoxynucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci USA. 1995;92:3318–3322. doi: 10.1073/pnas.92.8.3318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ladino CA, Chari RVJ, Bourret LA, Kedersha NL, Goldmacher VS. Folate-maytansinoids: target-selective drugs of low molecular weight. Int J Cancer. 1997;73:859–864. doi: 10.1002/(SICI)1097-0215(19971210)73:6<859::AID-IJC16>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
- 15.Kranz DM, Patrick TA, Brigle KE, Spinella MJ, Roy EJ. Conjugates of folate and anti-T-cell receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc Natl Acad Sci USA. 1995;92:9057–9061. doi: 10.1073/pnas.92.20.9057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Gottschalk S, Cristiano R, Smith L, Woo S. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther. 1994;1:185–191. [PubMed] [Google Scholar]
- 17.Mislick KA, Baldeschwieler JD, Kayyem JF, Meade TJ. Transfection of folate-polylysine DNA complexes: evidence for lysosomal delivery. Bioconjugate Chem. 1995;6:512–515. doi: 10.1021/bc00035a002. [DOI] [PubMed] [Google Scholar]
- 18.Douglas J, Rogers B, Rosenfeld M, Michael S, Feng M, Curiel D. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotech. 1996;14:1574–1578. doi: 10.1038/nbt1196-1574. [DOI] [PubMed] [Google Scholar]
- 19.Li S, Deshmukh H, Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res. 1998;15:1540–1545. doi: 10.1023/A:1011946915209. [DOI] [PubMed] [Google Scholar]
- 20.Zanta M-A, Boussif O, Adib A, Behr J-P. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjugate Chem. 1997;8:339–344. doi: 10.1021/bc970098f. [DOI] [PubMed] [Google Scholar]
- 21.Kircheis R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T, Buchberger M, Wagner E. coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 1997;4:409–418. doi: 10.1038/sj.gt.3300418. [DOI] [PubMed] [Google Scholar]
- 22.Guo W, Hinkle GH, Lee RJ. 99mTc-HYNIC-folate, a novel receptor-based radiopharmaceutical for tumor imaging. J Nucl Med. 1999;40:1563–1569. [PubMed] [Google Scholar]
- 23.Ciuchi F, Nicola GD, Franz H, Gottarelli G, Mariani P, Bossi MGP, Spada GP. Self-recognition and self-assembly of folic acid salts: columnar liquid crystalline polymorphism and the column growth process. J Am Chem Soc. 1994;116:7064–7071. doi: 10.1021/ja00095a008. [DOI] [Google Scholar]